Bhatia N et al. JAMA Dermatol. 2025;161(5):499.
Low-dose doxycycline is an established treatment for papulopustular features of rosacea that may reduce the adverse effects of doxycycline treatment; however, data on low-dose regimens for other tetracyclines are limited. In a 16-week randomized trial in over 650 adults with moderate to severe papulopustular features of rosacea, low-dose minocycline was more effective for improving disease severity and inflammatory lesion counts than low-dose doxycycline and placebo. Adverse events were similar between the groups, and no drug-related serious adverse events occurred. These findings support the use of low-dose minocycline for inflammatory lesions of rosacea in adults and contributed to U.S. Food and Drug Administration approval for this indication.